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Abstract: Approximately 200 human papillomaviruses (HPVs) infect human epithelial cells, of which
the alpha and beta types have been the most extensively studied. Alpha HPV types mainly infect
mucosal epithelia and a small group of these causes over 600,000 cancers per year worldwide
at various anatomical sites, especially anogenital and head-and-neck cancers. Of these the most
important is cervical cancer, which is the leading cause of cancer-related death in women in many
parts of the world. Beta HPV types infect cutaneous epithelia and may contribute towards the
initiation of non-melanoma skin cancers. HPVs encode two oncoproteins, E6 and E7, which are
directly responsible for the development of HPV-induced carcinogenesis. They do this cooperatively
by targeting diverse cellular pathways involved in the regulation of cell cycle control, of apoptosis
and of cell polarity control networks. In this review, the biological consequences of papillomavirus
targeting of various cellular substrates at diverse anatomical sites in the development of HPV-induced
malignancies are highlighted.
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1. Introduction
Persistent infection with the human papillomaviruses (HPVs) is the main risk factor in the
development of numerous human malignancies at various anatomical sites [1,2]. Of these, cervical
cancer is the most important disease, predominantly affecting women in developing countries and
causing more than 600,000 cancers annually [2,3]. Although around 200 HPV types are known to
infect humans, only a small proportion of these have been associated with cancer development [4,5].
HPVs are classified into five genera: alpha (α), beta (β), gamma (γ), mu (µ) and nu (ν), and the α and
β genera have been most intensively investigated [6]. The α-papillomavirus group contains members
which infect mucosal epithelia and which are divided into low-risk (LR) and high-risk (HR) types,
based on their ability to cause cancer. The LR viral infections result in benign lesions, commonly
caused by HPV-6 and HPV-11, while HR viral infections have been associated with malignancies
of anogenital and head-and-neck regions. Of these, HPV-16 and HPV-18 cause approximately 80%
of the world’s cervical cancer burden, while the remaining 20% are predominantly associated with
other HR HPVs such as HPV-31, HPV-33, HPV-45 and HPV-58 [7,8]. Interestingly, in HPV-positive
head-and-neck cancers, which primarily affect the oropharynx and occur in the tonsils and base of the
tongue, HPV-16 is most prevalent, while the other HR types are only rarely detected [9,10].
β-HPVs commonly infect cutaneous epithelia. Originally they were found to be present in
skin warts and in cutaneous squamous cell carcinomas (CSCC) of patients with the rare disease
epidermodysplasia verruciformis (EV) [11]. In EV patients, HPV-5 and HPV-8 have been characterized
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as potentially cancerogenic types [4,5]. CSCC development usually occurs a few decades after the
initial formation of benign skin lesions, predominantly in sun-exposed areas, indicating that the
primary infections occur early in life [12]. It had been thought that the mechanism of action of β-HPVs
in the development of skin cancer was equivalent to the mechanism of HR HPVs in cervical cancer
development. However, β-HPV genomes do not integrate in the host DNA [13], and there is no
evidence of continuous oncoprotein expression in CSCC, which suggests that β-HPVs may play a role
in tumour initiation, but not in tumour maintenance [11,14]. Furthermore, cellular transformation and
mouse model studies have indicated that, in the presence of UV damage, E6 and E7 from β-HPVs can
contribute towards initiation of cancer formation [15–17].
2. Viral Life Cycle Differences between Alpha and Beta-HPV Types
Alpha-HPV types infect mucosal epithelia and, as demonstrated in Figure 1, it is believed that
the virus enters through microinjuries and infects the basal cells of the epithelium. The viral life
cycle is strictly dependent upon the cellular differentiation of keratinocytes, the principal target cells.
The virus does not have its own replicative machinery and is therefore dependent upon cellular
division and stratification of the epithelium, which occurs from the basal layers towards the suprabasal
layers, exploiting this process to replicate and produce new viruses. In this process HPV oncoproteins,
E6 and E7, play a crucial role. Their joint action targeting of diverse cellular pathways involved in the
regulation of cell cycle control and apoptosis enables the virus to maintain cell proliferation in highly
differentiated suprabasal regions, allowing viral genome amplification to occur [1,18].
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Figure 1. From a productive HPV life cycle to cancer development. The left panel shows the proposed 
route of HPV infection via microinjuries in mucosal epithelium. There is a highly controlled 
expression of several viral gene products, where E6/E7 oncogenes, by targeting their respective 
substrates p53/pRb, promote continual cell proliferation. This allows the virus to amplify its genome, 
complete its productive life cycle and ultimately produce new virions. If the immune system of the 
host does not resolve the viral infection and it persists for a long period of time, this may result in 
HPV-induced malignancy, in which the virus fails to complete its life cycle, while the E6 and E7 
proteins are highly overexpressed. Adapted from [8]. 
Much information about the viral life cycle has been obtained from the organotypic raft culture 
model system, which reconstructs the full productive life cycle of HPVs in vitro [19]. In this system 
either the spontaneously immortalized keratinocyte cell line Normal Immortal Keratinocytes (NIKS) 
or Human Foreskin Keratinocytes (HFKs) immortalized by telomerase are used to recapitulate the 
replicative viral life cycle [20]. NIKS are very effective in supporting the life cycle of a number of HR 
α-types such as HPV-16, -18, -31, -45 and -58, while the immortalized HFKs have been used to study 
the life cycle of some of the LR types such as HPV-11 [21–23]. However, there are some limitations to 
this model of studying HR HPV viral life cycles, since all the analyses are performed in the same 
cellular background. It is very well known that HPVs infect various anatomical sites, which have 
different epithelial backgrounds and there is a high possibility there could be significant differences 
Figure 1. From a productive HPV life cycle to cancer development. The left panel shows the proposed
route of HPV infection via microinjuries in mucosal epithelium. There is a highly controlled expression
of several viral gene roducts, where E6/E7 oncogenes, by targeting their respective substrates
p53/pRb, promote continual cell proliferation. This allows the virus to amplify its gen me, complete
its productive life cycle and ultimately produce new virions. If the immune system of the host does
not resolve the viral infection and it persists for a long period of time, this may result in HPV-induced
malignancy, in which the virus fails to complete its life cycle, while the E6 and E7 proteins are highly
overexpressed. Adapted from [8].
Much information about the viral life cycle has been obtained from the organotypic raft culture
model syst m, which reconstructs the full p odu ive life cycle of HPVs in vitro [19]. In this system
either the spontaneously immortalized keratinocyte cell line Normal Immortal Keratinocytes (NIKS)
or Human Foreskin Keratinocytes (HFKs) immortalized by telomerase are used to recapitulate the
replicative viral life cycle [20]. NIKS are very effective in supporting the life cycle of a number of HR
α-types such as HPV-16, -18, -31, -45 and -58, w le the mmortalized HFKs have been used to study
the life cycle of some of the LR types such as HPV-11 [21–23]. However, there are some limitations
to this model of studying HR HPV viral life cycles, since all the analyses are performed in the same
cellular background. It is very well known that HPVs infect various anatomical sites, which have
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different epithelial backgrounds and there is a high possibility there could be significant differences
in the viral life cycle depending on the cell origin. Unfortunately, owing to these limitations there is
currently no solid information about the viral life cycle at other sites of infection, although studies
have reported the detection of HPV-16 L1 protein in virus-infected areas such as tonsils, indicating the
ability of the virus to complete its productive life cycles in the oropharyngeal region [24]. Therefore,
there is a pressing need to extend existing organotypic raft culture systems to cells isolated from other
anatomical sites to better understand potential differences in the productive life cycle of the virus.
There have been few successful attempts to study β-HPVs life cycles; although some limited
information has been obtained from organotypic raft culture studies that have shown certain
similarities between LR α types and β types. Like HPV-11, HPV-8 episomal genomes are not well
maintained in tissue culture and tend to be lost over time. In addition, it appears that HPV-8 viral
genomes do not increase the cellular growth rate, which is why the complete HPV-8 life cycle has not
been reproduced in this in vitro system [14,25]. This could be partly attributed to β-HPV types not
expressing an E5 protein, which in α-HPVs can contribute to genome amplification by stabilizing the
EGFR [16,26–28]. In addition, HPV E5 protein also has additional functions that contribute to optimal
life cycle completion, for example, HR HPV-16 E5 inhibits the EVER/ZnT-1 protein complex, which is
involved in maintaining the cellular zinc balance which plays a role in controlling HPV infections [29].
Since the β-HPV types do not encode E5 they cannot inhibit EVER proteins in the same way. However,
mutations in either of two genes (EVER1 and EVER2) were shown to be causative or contributive
agents in most EV cases, and might thereby contribute indirectly to β-HPV infections. This might
partially explain the host restrictions for infections with β-HPV types [29,30].
3. The Role of the High Risk Alpha E6 and E7 in Pathogenesis
The normal productive viral life cycle of the HR α-types is a highly regulated and coordinated
process. However, in some instances, mostly during persistent infection, the viral DNA is randomly
integrated into the host genome, leading to cellular immortalization and eventually to malignant
progression. The outcome of this process is the collapse of the viral replicative capacity: most of the viral
genes are lost while the two major viral oncogenes, E6 and E7, remain uncontrollably expressed, driving
cellular immortalization, further progressing towards cellular transformation, and ultimately resulting
in cancer development [31,32]. Interestingly, the process of viral integration occurs much less frequently
in oropharyngeal carcinomas than in cervical cancer [33]. The importance of E6 and E7 in maintaining
the transformed phenotype can be seen from their continual expression in tumors and derived cell
lines many years after the primary immortalizing events. This was observed in numerous studies
which demonstrated that any inference with these oncogenes at either the RNA (ribozymes, anti-sense
RNA and RNA interference) or protein levels (blocking peptides) will lead to cell growth arrest and/or
apoptosis [34–39]. Moreover, it has been shown that the complementary activities of E6 and E7 are
required to immortalize primary human keratinocytes; E6 interfering with cell survival pathways and
E7 promoting cellular proliferation [40–42]. In contrast, neither E6 nor E7, when expressed alone, had
any significant impact on cellular immortalization. Transgenic mouse model cervical cancer studies
showed that E7 increased proliferation and centrosome copy number and induced the progression of
multifocal microinvasive cervical cancers; while E6 elevated centrosome copy number and eliminated
detectable p53 protein, but did not produce neoplasia or cancer. Importantly, the combination of both
oncoproteins resulted in increased centrosome number and large, extensively invasive, cancers [43].
Similar observations were seen in models of head-and-neck squamous cell cancers (HNSCC).
In these, E7 was shown to be the major transforming oncoprotein, whereas E6 appears to be more
likely to play a secondary role in contributing to the later stages of malignancy [44]. Based on these
studies, a model of HPV-induced carcinogenesis has been developed and is summarized in Figure 2.
Thus, these two oncoproteins are considered to be excellent targets for therapeutic intervention,
and understanding the molecular mechanisms underlying their respective functions is critical for
developing such antiviral therapies.
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By targeting pRb E7 promotes tumor formation and contributes to the early stages of HPV-driven
malignancy. It is believed that the later stages of malignancy are in part driven by E6 and its ability
to target the PDZ-domain containing cellular substrates via its C-terminal PDZ-binding motif (PBM).
Adapted from [45].
3.1. Alpha-HPV E6
3.1.1. p53 and Components of the Proteasome Ubiquitin Pathway as Interacting Partners of
Alpha-HPV E6
The HPV E6 protein is approximately 150 amino acids long and has two zinc fingers formed by
two pairs of CXXC motifs [46,47] (Figure 3A). These motifs are strictly conserved in all E6 proteins
and their integrity is essential for the oncoprotein’s normal functions [48,49]. The crystal structures
of both N-terminal and C-terminal halv s, as well as the complete structure of the E6 proteins have
been resolved [50–52]. These structural studies have addi ionally confirmed the fact that E6 i teracts
with a wide range of cellular substrates [53]. The principal cellular target of HR E6 proteins is the
tumor suppressor p53. In the absence of HPV, p53 is regulated by the RING finger domain-containing
ubiquitin ligase Mdm2 [54]. However, under stress, such as upon DNA damage or viral infection,
this process is abolished and p53 is both stabilized and activated by a series of phosphorylation
events [55]. In HPV-positive cancer cells, the Mdm2 pathway is completely inactive and p53 turnover
is regulated by HPV E6 [56]. In addition to p53 protein re lati , which can be proteasome-dependent
or -independent, α-HPV E6s are also involved in regul tion of p53 gene transact vati n. It was shown
that E6 mut nts unable to induce p53 degradation can still bolish p53 transcriptional trans ctivation
activity [57]. E6 can also control p53-dependent gene regulation, via its interactions with p300/CBP
co-activators [58,59]. Additionally, it was demonstrated that E6-interacting regions of p300 are
necessary for E6 to inhibit p53-dependent chromatin transcription, and that the E6-mediated repression
of p53-dependent activation correlates with inhibition of acetylation on p53 and nucleosomal core
histones, altering p53 and p300 recruitment to chromatin. This process is a unique way in which E6
repress s p53 whic does not r quire the proteas me [60].
On its own, E6 cannot targ t p53 for proteasomal degradation, rather, it hijacks a cellular E3
ubiquitin ligase UBE3A/E6AP (E6-associated protein), binding through E6’s LXXLL motif, and the
stable E6/E6AP complex then labels p53 for degradation in a proteasome-dependent manner [61–64].
Recent studies have further emphasized the importance of the E6/E6AP association, showing that the
stability of HR α-HPV E6 proteins is critically dependent upon the presence of E6AP [65]. A number of
studies have shown E6 to be closely associated with other components of the proteasome degradatory
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pathway: in addition to E6AP, HR α-HPV E6 interacts with the E3 ubiquitin ligases UBR5/EDD
and HERC2 [66,67]. It has been shown that changes in the UBR5/EDD protein levels throughout
the viral life cycle, or during malignancy, might affect E6’s ability to target its cellular substrates for
proteasomal degradation, and thus might have a direct impact on the development of HPV-induced
malignancy [66]. In addition, HR α-HPV E6s interact directly with the S5a proteasome subunit, one of
the two major ubiquitin acceptor molecules of the proteasome. The interaction is E6AP-dependent and
results in the upregulated ubiquitination of S5a, indicating the complexity of E6 association with the
proteasome [68].
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Figure 3. The high-risk HPV E6 and E7 oncoproteins. (A) Schematic diagram of HPV-16 E6 showing
the position of amino acid motifs that are important for protein integrity and function. The two zinc
fingers are shown, together with regions that are involved in interacting with some of its cellular
target proteins. The C-terminal PBM is shown and the PKA phosphorylation site is also indicated;
(B) Schematic diagram of E7 and the most important amino acid motifs required for integrity and
protein functions. Three regions of E7 that are homologous to adenovirus E1A conserved regions
1-3 (CD1-3) are shown. The zinc finger is also shown, together with the regions involved in pRb
binding (LXCXE) and the two serine residues (31 and 32) that are susceptible to casein kinase II
(CKII) phosphorylation.
3.1.2. Alpha-HPV E6 and Apoptosis
Although the major anti-apoptotic activity of E6 is its inactivation of p53, it also has a number
of other cellular pro-apoptotic targets, including Bak. Bak is highly expressed in the upper epithelial
layers, indicating that it could play a role in terminal differentiation [69]. After UV exposure it is
activated and stabilized independently of p53 [70] and HPV E6 targets Bak for E6AP-dependent
proteasome-mediated degradation, thereby directly inhibiting apoptosis [15,71,72]. LR HPV types,
such as HPV-11, also target Bak for proteasome-mediated degradation, however their capacity
to degrade Bak is fairly weak, which correlates with a reduced anti-apoptotic activity of the LR
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mucosal types [72]. In addition to Bak, other cellular proteins involved in apoptosis regulation
have been reported as E6 targets: survivin was identified as an indirect target of HPV E6, which
strongly upregulates survivin promoter activity, again resulting in the suppression of apoptosis [73].
Furthermore, E6 also interacts with other components of the host apoptotic machinery, such as the
tumor necrosis factor receptor 1 (TNF R1) [74], the adaptor molecule Fas-associated death domain
(FADD) [75], and procaspase 8 [76]. E6 interacts with procaspase 8 and FADD through their death
effector domains (DEDs) and mediates the accelerated degradation of both proteins.
3.1.3. Alpha-HPV E6 and DNA Replication
In addition to their association with pro-apoptotic cellular proteins, HR E6 oncoproteins are also
involved in the deregulation of the cellular DNA replication machinery. Normal somatic cells end
their life by entering senescence, which results from the progressive shortening of telomere DNA over
successive rounds of replication, and most normal cells do not exhibit telomerase activity [77]. However,
activated telomerase is found in cells of cervical carcinomas and high-grade lesions induced by HR
HPVs, preventing shortening of the telomeres and leading to continued proliferation [78]. HPV-16
E6 induces telomerase activity in primary epithelial cells through transcriptional transactivation of
the hTERT telomerase catalytic subunit [79,80], which probably requires the presence of an intact E
box in the minimal hTERT promoter [80–82]. HPV-16 E6 hTERT activation was shown to require E6
binding to Myc [81,83], but not to E6AP [84]. On the other hand, E6/E6AP-dependent degradation of
the transcriptional repressor NFX1-91, which binds to the hTERT promoter, causes the mSin3A/HDAC
complex to dissociate from the hTERT promoter, inducing hTERT transcription [85]. Thus, although
the exact mechanism of activation seems to be controversial, hTERT activation by E6 appears to be
a crucial step for HPV-induced malignancy.
3.1.4. Alpha-HPV E6 and PDZ Domain-Containing Proteins as Interacting Partners
All HR α-HPV E6 proteins have a class I PDZ (PSD95/Dlg/ZO-1)-binding motif (x-T/S-x-L/V [86])
at their C-termini. PDZ domains are approximately 90 amino acid protein-protein interaction
domains [87] and PDZ domain-containing proteins fall into three main groups: PDZ-only proteins;
Membrane associated guanylate kinases (MAGUKs); and PDZ proteins with other binding
domains [88]. PDZ domain-containing proteins typically function as scaffolds that assemble signaling
complexes and localize them to specialized regions of cell-cell contact, such as Adherens and Tight
Junctions [87]. The two major HR types, HPV-16 and HPV-18, are known to interact with numerous
PDZ-domain containing proteins via their PDZ-binding motifs (PBMs) [8,45]. Several of these are
involved in the regulation of epithelial cellular polarity, emphasizing the importance of this pathway for
both viral replication and for HPV-driven malignancy, as has been shown in both tissue culture [89,90]
and transgenic animal model systems [91]. The PBM is also important in the viral life cycle, since its
loss in the context of an intact viral genome reduces viral replicative potential and very often leads to
episomal integration [92,93].
The specificity of the PDZ interaction is an important factor in E6-PDZ target recognition, and
different E6 proteins interact preferentially with different PDZ domain-containing proteins [1,8,45,94].
For example, HPV-18 E6 binds more strongly than HPV-16 E6 to Dlg1 and MAGI-1 [89], and
exchanging the last amino-acid residue of HPV-16 E6 (L) for that of HPV-18 E6 (V) reverses this
phenotype [95]. Conversely, HPV-16 binds hScrib more strongly than HPV-18 E6 and this is also PBM
sequence-dependent [96]. Interestingly, several of E6’s PDZ domain-containing targets are potential
tumor suppressors, with hScrib being an excellent candidate for a tumor suppressor in diverse cancer
settings [97,98]. The importance of the exact PBM sequence in substrate recognition was supported by
crystal structure studies which showed that a peptide homologous to the HPV-18 E6 carboxy-terminus
binds differently to different PDZ domains [99,100]. Interestingly, Rhesus papillomavirus 1 (RhPV 1),
a HR mucosal type whose E6 and E7 oncogenes share approximately 50% homology with those of
HPV-16, has no C-terminal PBM on E6; instead a PBM is found on the E7 C-terminus. This is also
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a class I PBM, but with a significantly different sequence from those of HPV-16 and HPV-18 [8,101].
Correspondingly, the preferred target of the RhPV-1 E7 PBM also differs, and is the cell polarity
regulator Par3, which it targets in part for proteasome-mediated degradation [101]. This demonstrates
a remarkable evolutionary conservation of this activity between HR virus types—to target the same
cell polarity control pathway by similar means, but through different proteins.
3.1.5. Phospho-Regulation of Alpha-HPV E6 PDZ-Binding Motif
Interestingly, the HR PBM can also be post-translationally regulated. It contains a protein
kinase A (PKA) phospho-acceptor site, and its phosphorylation by either PKA or AKT blocks PDZ
binding and instead allows E6 to interact with 14-3-3ζ [102], a member of the 14-3-3 family of
phospho-threonine/serine interacting proteins [103], which are involved in the regulation of a number
of cellular processes directly relevant for cancer progression and malignant development. The intact
PBM is necessary for interactions between E6 and 14-3-3ζ, and downregulation of 14-3-3ζ leads to
a dramatic decrease of E6 protein levels in HPV-18 positive HeLa cells [102]. It was also shown that
the phosphorylation-dependent switch between PDZ- or 14-3-3ζ-binding activity is dependent upon
the different susceptibilities of the individual HPV types to PKA or AKT phosphorylation of the
PBM. This regulation was shown to be well-conserved between HPV-16, HPV-18, and HPV-58 E6s,
but somewhat weaker between HPV-31, HPV-33, and HPV-51 E6s [104]. All of this highlights the
importance of the PBM and its role in HPV-induced carcinogenesis.
3.2. Alpha-HPV E7
HPV E7 is a 98 amino acid protein that has a C-terminal zinc-binding domain, whose structural
integrity is critical for E7 activity [105,106]. The protein contains three conserved domains, CD1, CD2,
and CD3 (Figure 3B): CD1 and CD2 correspond to small parts of conserved regions 1 and 2 (CR1 and
CR2) of Adenovirus E1a, while CD3 is homologous to SV40 large T antigen. The overall integrity
of the protein is critical for optimal E7 interactions with its cellular substrates, although most of the
characterized functions of E7 have been mapped to the CD2 and CD3 regions [107] (Figure 3B).
E7 is post-transcriptionally regulated by the proteasome and by phosphorylation. It interacts
with the Skp-Cullin-F box (SCF) ubiquitin ligase complex, which leads to increased ubiquitination of
the protein [108]. It has been also demonstrated that Casein Kinase II (CKII) phosphorylation of the
E7 N-terminal domain is critical for its transformational activity [109,110]. An additional C-terminal
phosphorylation site has been identified which seems to be phosphorylated primarily during the
S phase, but the kinase responsible has not been determined [111].
3.2.1. Conserved Domains of Alpha-HPV E7
The CD1 domain comprises the first 20 amino acids of E7 and is critical for E7’s ability to
induce S-phase progression and cellular transformation [112–114] (Figure 3B). Among the binding
partners that interact with this domain of E7 are UBR4/p600 [115] and p300/CBP-associated factor
(P/CAF) [116]. UBR4/p600 is essential for membrane morphogenesis, which is crucial for cell
migration, and is also required for cell survival [117] and anchorage-independent growth in both
HPV-negative and HPV-positive cells. Interaction between E7 and UBR4/p600 is thought to be required
for E7-mediated cell transformation [118], but its exact function in E7’s activities still remains to be
determined. More recent studies have shown that E7 proteins from many HPV types, including those
that are not cancer-associated, interact with UBR4/p600; and it has been speculated that UBR4/p600
could play a role in viral replication [119]. On the other hand, the consequences of the E7 and P/CAF
interaction appear to be more straightforward, since E7 has been shown to down-regulate the P/CAF
mediated activation of NF-κβ family members, which occurs during viral infection, resulting in viral
escape from the immune response [116].
Amino acid residues from 20 to 38 constitute the CD2 region of E7 (Figure 3B). This contains
the CKII phosphorylation site and the LXCXE binding motif involved in binding to proteins such as
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the retinoblastoma tumor suppressor (pRb). As mentioned above, the CKII phospho-acceptor site is
important for E7’s transforming capacity [110,120] and for its ability to drive S-phase progression [121],
while interaction with the pocket proteins has been characterized as one of the major functions of E7.
pRb has a critical role in cell cycle regulation, controlling the G1 to S phase transition.
Under normal conditions, pRb is unphosphorylated in early G1 and is progressively phosphorylated
towards S phase. Unphosphorylated pRb interacts with the E2F transcriptional factors and acts as
a transcriptional repressor of promoters containing E2F sites [122]. E2F family members are involved
in the cell cycle-dependent transcriptional regulation of many genes involved in DNA synthesis [123].
In the HPV-positive cell, E7 uses its LXCXE motif to target unphosphorylated pRb for degradation [124]
via the ubiquitin proteasome pathway [125], and HPV-16 E7’s association with the cullin 2 complex
contributes to this process [126]. Disruption of the pRb-E2F complex releases free E2F, which results in
E2F-induced transcription leading to upregulation of CDK2 and cyclins A and E. This activity of E7 is
considered critical for driving cell cycle progression in a differentiating epithelium, thus providing
an environment suitable for DNA replication.
In addition to the pRb interaction, E7 also binds to the other pocket proteins p107 and p130.
These play important roles in the regulation of cellular proliferation, differentiation and apoptosis,
through their interactions with different molecules [127]. They inhibit E2F-mediated transcription
and negatively regulate the transitions from G0 to G1, and into the S phase of the cell cycle [128],
and the integrity of the pocket proteins is also required for controlling the permanent exit from the
cell cycle in G2 [129]. p107 is primarily expressed in proliferating cells and inhibits E2F4 [130], while
p130 is predominantly found in non-proliferating cells and inhibits E2F5 activity [131]. In addition,
recent studies have shown that E7 binds and inactivates E2F6, a protein that interacts with polycomb
complexes, leading to changes in epigenetic profile linked to gene silencing [132,133]. Importantly,
the same LXCXE motif of the E7 CD2 domain that has been shown to be required for pRb inactivation
is also required for down-regulation of p107 and p130 [134]. This again points out the necessity
for the interaction of E7 with the pocket proteins for its optimal ability to continually drive cell
cycle progression.
Amino acid residues 38–98 constitute the C-terminal CD3 region (Figure 3B), which contains
four highly conserved cysteine residues and is involved in interactions with numerous cellular proteins,
including the p21 and p27 CDK inhibitors, whose activities E7 abrogates as a necessary step in inducing
cell cycle progression and overcoming DNA damage-induced cell cycle arrest; although other E7
domains are also involved in these interactions [134,135]. E7 is also involved in induction of protein
kinase B (PKB) phosphorylation of p21, thereby abrogating its nuclear activities [136]. The E7 CD3
domain also binds to the Mi2β component of the histone deacetylase (HDAC) complex [137], inhibiting
its activity and, leading to upregulation of the E2F gene through acetylation of the E2F promoter [138].
The E7 CD3 also binds TBP [139], and the hTid-1 protein, a member of the DnaJ-family of chaperones.
The large tumor antigens of polyomaviruses, including SV40, contain J-domains that are important for
viral replication, as well as for cellular transformation, and the fact that E7 interacts with a cellular
DnaJ protein implies that these two oncoproteins could target common regulatory pathways via
J-domains [140]. In addition to its main role in driving cell cycle progression, the interactions with
substrates described above also indicate that E7 has a crucial role in destabilizing transcriptional
complexes and in chromatin remodeling, consequently having an impact on cellular proliferation.
3.2.2. Alpha-HPV E7 and Centrosomal Abnormalities
Centrosomes are the major microtubule organizing centers in the majority of animal and human
cells [141]. Under normal conditions, each of the two centrioles that make up a G1 phase centrosome
functions as a template for exactly one newly synthesized daughter centriole [142]. To prevent any
possible multipolar mitoses or chromosomal instability [143,144], cells go through a single round
of centriole duplication per cell division [145]. In contrast, tumor cells frequently have multiple
centrosomes [146]. It is believed that aberrant centrosome numbers develop through cell division
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collapse or via genuine disruption of the centriole duplication cycle itself [147]. In addition, many
oncogenic stimuli appear to result in the induction of abnormal centrosome and centriole numbers
in vitro, but the precise mechanisms still need to be resolved.
Both E6 and E7 oncoproteins have been shown to independently cause centrosomal abnormalities
when stably expressed in cell culture and in transgenic mouse models [43,148]. However, ectopic
E7 expression in primary and tumor-derived cells rapidly stimulates elevated centrosomal numbers,
in some cases even before the cells progress to malignancy. This might suggest that E7 has a direct
effect on centrosome duplication [149], or it might occur as a consequence of E7 interacting with the p53
pathway [150], it having been shown to be pRb-independent [151]. More recent mechanistic studies
have shown that E7-stimulated cyclin/CDK2 activity is crucially involved in the abnormal centrosome
duplication [152]. Furthermore, it has also been reported that continuing RNA pol II-mediated gene
transcription is required for HPV-16 E7-induced centriole overduplication, but not for normal centriole
duplication and cell cycle progression [153].
4. High Risk α-HPV Infections at Different Anatomical Sites
4.1. Cervix
The most extensively investigated site of HPV-induced malignancy is the anogenital region, where
almost all cancers arise at the cervical or anal transformation zones [154,155], where the stratified
and columnar epithelia meet. It is unclear why this region is particularly susceptible to HPV-induced
transformation, but it could be due to mis-regulation of viral gene expression, resulting in failure
of the productive life cycle [156,157]. The cervical transformation zone contains specialized cells
known as reserve cells [158] and also has a population of cuboidal cells at the squamo-columnar
junction [159,160]. Depending on the environment, these cells can support either the stratified
epithelium of the transformation zone or the columnar epithelium of the endocervix. In the ectocervix,
a population of conventional epithelial stem cells is also present. It is thought that the individual cell
type characteristics determine the fate of any given HPV infection. The pattern of viral gene expression
may vary depending on the cell type, which might ultimately result in different outcomes [161].
The currently existing model argues that productive viral life cycles are likely to be completed at the
ectocervix, while a collapse of the viral life cycle or incomplete infection is more likely to occur at the
endocervix [154].
4.2. Head-and-Neck Region
Recently, HR HPV infections have also been associated with a number of head-and-neck cancers
(HNSCC), the majority occurring in the oral cavity and the tonsillar crypts [162–165]. The tonsillar
crypts are lined with a specialised squamous epithelium, reticulated epithelium, which is infiltrated
with lymphoid tissue, fragmenting the epithelial barrier [165]. The cells here are “basaloid”, suggesting
susceptibility to HPV infection, and this is also thought to be an immune-privileged zone, facilitating
immune evasion by the virus. Equally importantly, this tissue does not maintain the polarization
and surface maturation found in stratified squamous epithelium. Thus, this tissue may be uniquely
susceptible to HPV-induced carcinogenesis, having three weaknesses: lack of barrier and basal cell
type allowing easy infection; immune privilege preventing clearance; and reduced polarisation of
the epithelium increasing the likelihood of a persistent infection—a major risk-factor for malignancy.
The overwhelming majority of HPV-related cancers in these areas are HPV-16 positive, with a very low
proportion of other HR HPV types, such as 18, 31, and 33 [4,5,166–168], and the reasons for this are not
yet clear. Interestingly, the time between initial infection and disease development in head-and-neck
cancers is much shorter than in anogenital cancers [169]. All this suggests a complex interplay between
the virus and the replicative environment in this anatomical site.
About 80% of cervical cancers are caused by HPV-16 and HPV-18 and many E6 and E7 cellular
targets are common to both virus types, with any differences lying only in the degree of interaction.
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In contrast, virtually nothing is known about their cellular substrates in the oropharynx, which may
be very different owing to the tissue complexity and the surrounding environment. Biochemical
and mechanistic studies of the viral oncogenes and their interacting partners in oropharyngeal
cells are needed to clarify potential differences both in the productive life cycle of the virus and
in virus-induced malignancy.
5. The Beta E6 and E7 Proteins
The E6 and E7 oncoproteins of the β-HPV types share some common interacting partners and affect
similar cellular pathways as the HR α-HPV oncoproteins, but there are also some significant differences.
5.1. Beta-HPV E6
5.1.1. Ubiquitin Ligases and p53 as Interacting Partners of Beta-HPV E6
Unlike HR α-types, the majority of the β-type E6 proteins do not target p53 for
proteasome-mediated degradation [170]. However, some, such as HPV-49 E6 can target p53 for
E6AP-dependent proteasome-mediated degradation [171], whereas others, such as HPV-38 and
HPV-92 E6 proteins bind to p53, but in contrast to the HR α-types, they appear to stabilize p53 [119].
Most β-type E6s do not bind E6AP or bind it only weakly in vivo, which could explain, at least in
part, why most of them do not target p53 for proteasome-mediated degradation. Interestingly, in vitro
analyses have shown that HPV-38 E6 binds strongly to GST-E6AP, while HPV-24 E6 barely binds
to GST-E6AP, yet co-expression of E6AP in cells appears to stabilize the E6 proteins of a number of
β-HPV types, type 24 included. This suggests that additional proteins or protein modifications may
contribute to HPV-24 E6 binding to E6AP [172]. In addition, HPV-38 E6 interacts with the ubiquitin
ligase p600/UBR4, but the consequences of this interaction are still unclear [172].
5.1.2. Beta-HPV E6 and NOTCH Signaling
β-type E6 proteins interact very strongly with MAML1, through a binding motif similar to the
LXXLL motif used by α-type E6s to bind E6AP [119,173]. MAML1 is a transcriptional co-activator of
Notch-regulated genes and the binding of β-HPV E6s proteins inhibits Notch signaling; at least in
the case of HPV-8 E6, by inhibiting RBPJ/MAML1 transactivation complexes. Since Notch inhibition
slows epithelial differentiation, this might affect viral replication and could also contribute to viral
oncogenesis [174]. Interestingly, α-type E6s preferentially interact with E6AP, while the majority of
the β-type E6s were shown to interact with MAML1 [119]. It is likely that these differences in binding
preferences were evolutionary adaptations of the viruses to the differences in the tissue in which
they replicate. Moreover, E6 targeting MAML1 could have been a crucial adaptation, allowing these
viruses to replicate in cutaneous epithelia, since in keratinocytes Notch signaling supports cellular
differentiation and growth arrest [175,176].
5.1.3. Beta-HPV E6 and p53 Gene Regulation
Like α-HPV types, β-types also interfere with the expression of p53-regulated genes by associating
with the transcriptional co-activators CBP and p300. The E6s from HPV-5, HPV-8 and HPV-38 all
interact with p300 [16,177], and HPV-8 E6 was also shown to induce p300 degradation [16], dramatically
reducing the levels of ATR protein, which plays a critical role in UV-induced damage signaling.
This results in an increase in thymidine dimer mutations upon exposure to UV irradiation [16].
The HPV-38 E6 interaction with p300, on the other hand, blocks p53 acetylation and inhibition of its
transcriptional functions [177]. In addition, HPV-23 E6 can block UV-induced p53 phosphorylation at
residue serine 46, via its association and inhibition of HIPK2 kinase [178].
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5.1.4. Beta-HPV E6 and Telomerase
The E6 proteins of β-HPV types 5, 20, 22 and 38 also associate with and activate hTERT in
an E6AP-dependent manner, albeit to a lesser extent than HPV-16 E6, but the E6 proteins from other
β-types show a significantly lower ability to activate telomerase [179]. Furthermore, the intensity of
the telomerase activation appears to be directly dependent on the strength of association between
E6 and E6AP or NFX-91. Therefore, HPV-38 E6, which interacts strongly with E6AP was shown to
efficiently immortalize primary HFKs in cooperation with E7 [180,181].
5.1.5. Beta-HPV E6 and Apoptosis
Like the α-type E6 proteins, the β-HPV E6s can abolish p53-dependent and -independent
apoptosis, which is induced in cutaneous sites in response to UV-induced DNA damage [70]. β-types
can also inhibit the pro-apoptotic protein Bak and drive its proteasomal degradation; this process is
also E6AP-dependent. Recently it has been suggested that the HERC1 ubiquitin ligase is required for
HPV-5 E6-mediated Bak degradation [182]. Bak proteins levels are undetectable in HPV-positive skin
cancers, in contrast to HPV-negative cancers, which express Bak, and which presumably abrogate the
apoptotic response at a different point in the pathway [70,71,183]. Thus, Bak is one of the few highly
conserved targets of both α- and β-type HPV E6 proteins.
5.2. Beta-HPV E7
Cellular interacting partners of β-HPV E7 proteins have not been as well-characterized as those
of the α-type HR E7s. However, they also contain an intact LXCXE binding motif and interact with
the pocket proteins pRB, p107 and p130 [184,185], but only HPV-38 E7 has yet been shown to induce
pRb degradation, and then only in rodent fibroblasts: in human keratinocytes it inhibits pRb function
by inducing its phosphorylation [171,180]. Another binding partner common to both α- and β-types
is the UBR4/p600 ubiquitin ligase, but the significance of this interaction in the viral life cycle is still
unclear [119].
In addition to its role in regulating cell cycle progression, HPV-38 E7 was shown to induce
changes in p53-regulated gene expression [186–188]. It cooperates with E6 to induce p53 stabilization
in the skin of transgenic mice, which then selectively induces transcription of the ∆Np73α isoform
of p73. This, in turn, blocks p53’s transcriptional activation of genes involved in regulation of cell
growth and apoptosis [186,187]. Furthermore, HPV-38 E7 was shown to directly regulate IKKβ
nuclear translocation and ∆Np73α accumulation: these two, together with DNA methyltransferase 1
(DNMT1) and enhancer of zeste homolog (EZH2) form the ∆Np73α/IKKβ/DNMT1/EZH2 complex,
which inhibits a number of p53-regulated promoters [188]. Additionally, immortalization of skin
keratinocytes by HPV-38 E6/E7 is associated with hTERT gene overexpression, which is partly due to
∆Np73α accumulation. However, during proliferation HPV-38 E6/E7-positive keratinocytes show
incomplete induction of telomerase with consequent telomere shortening, which leads to genomic
instability and may contribute to cellular immortalization [181,189].
Only two β-HPV types, HPV-8 and HPV-38, have actually been shown to promote tumorigenesis
in transgenic mouse models [190,191]. When either the HPV-8 early region, HPV-8 E6 or HPV-38
E6/E7 were expressed from a K14 promoter, this resulted in the formation of epidermal hyperplasia
and, occasionally, squamous carcinomas. In addition, UV irradiation greatly increased the numbers of
squamous cell carcinomas in these mice at levels that did not induce tumors in nontransgenic mice.
6. β-HPV Infections of Cutaneous Epithelia
The environment of viral infection of the β-HPV types is significantly different from the
environment where HR α-types infect their host cells. Different β-HPV types infect and cause lesions in
various different types of skin, commonly in proximity to hair follicles or nails, as well as between the
digits and at the eccrine and apocrine sweat apparatus [154], all of which are regions where different
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tissue types are in close proximity. The majority of cutaneous stem cells are located in the buccal
area of the hair follicles [192,193] and it is believed that the virus reaches those cells either through
microinjuries or via hair follicles. Between the hair follicles, the tissue stem cells are located at the rete
ridges and the dermal papilla (fingerprints) [194]. In the sweat glands, there are two distinct stem
cell populations, located either in the gland or the duct, and both of which are susceptible to β-HPV
infection, It has been demonstrated that these cells repair damaged skin, and HPVs are believed to
gain access to these stem cell populations either via microtraumas or via the eccrine duct [154].
7. Conclusions
It is becoming clear that whilst there are some intriguing similarities between alpha and beta HPV
types, there are also many major differences, and this is most likely a reflection of their differing sites
of replication. In addition, it is also apparent that the same virus type, for example HPV16, might well
display different properties depending upon the site of infection. Certainly its cancer-causing activity
appears to be much higher in tissues with a transformation zone, such as the cervix, anus or nail-bed,
than in those without. Thus, whilst we are gaining a greater understanding of how the viral
oncoproteins function, there is still much to learn about their respective activities in different tissue
types and environmental settings.
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